Article
Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.
Breast cancer research and treatment - 1 Apr 2013
Henry N Lynn, Skaar Todd C, Dantzer Jessica, Li Lang, Kidwell Kelley, Gersch Christina, Nguyen Anne T, Rae James M, Desta Zeruesenay, Oesterreich Steffi, Philips Santosh, Carpenter Janet S, Storniolo Anna M, Stearns Vered, Hayes Daniel F, Flockhart David A
Abstract excerpt
Up to 25 % of patients discontinue adjuvant aromatase inhibitor (AI) therapy due to intolerable symptoms. Predictors of which patients will be unable to tolerate these medications have not been defined. We hypothesized that inherited variants in candidate genes are associated with treatment discontinuation because of AI-associated toxicity. We prospectively evaluated reasons for treatment discontinuation in women...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.